Physical Activity Directly Before Immunotherapy (Nivolumab and Ipilimumab) in Melanoma

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Physical Activity Directly Before Immunotherapy (Nivolumab and Ipilimumab) in Melanoma | stella

Back to Metastatic Melanoma trials

Recruiting

This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.

Trial locations(1 site)

Germany

University Medical Center Hamburg-Eppendorf, Hamburg, Free and Hanseatic City of Hamburg

Key details

Sponsor

Universitätsklinikum Hamburg-Eppendorf

Enrollment target

~40 participants

View full record on ClinicalTrials.gov

Started

November 2025

Primary completion

December 2027

Last updated on clinicaltrials.gov in May 2026.

Contact the research team directly

Reach out to the team running this trial. Response times vary — some teams are faster than others.

Central contact

Joseph Tintelnot, MD

Universitätsklinikum Hamburg-Eppendorf

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Enrollment status is pulled from ClinicalTrials.gov and may not reflect real-time availability. If a trial appears full when you reach out, the team will let you know.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.